Clinical Trial Update: A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tirzepatide in combination with a progestin-releasing intrauterine device to treat endometrial hyperplasia and FIGO Grade 1 en…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Hyperplasia
• Endometrial Intraepithelial Neoplasia
• Endometrioid Endometrial Adenocarcinoma

Drugs mentioned

• Levonorgestrel-Releasing Intrauterine System (levonorgestrel-releasing intrauterine system)
• Tirzepatide (tirzepatide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING